Shuk Tak Kwok

Dr. Shuk Tak Kwok

The University of Hong Kong
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SNSiew Fei Ngu
Siew Fei Ngu
YCYu Ka Chai
Yu Ka Chai
KCKa Man Choi
Ka Man Choi
TLTsin Wah Leung
Tsin Wah Leung
JLJustin Li
Justin Li
KCKaren KL Chan
Karen KL Chan
The accurate prediction of malignancy for a pelvic mass detected on ultrasound allows for appropriate referral to specialised care. IOTA simple rules are one of the best methods but are inconclusive in 25% of cases, where subjective assessment by an expert sonographer is recommended but may not always be available. In the present paper, we evaluate the methods for assessing the nature of a pelvic mass, including IOTA with subjective assessment by expert ultrasound, RMI and ROMA. In particular, we investigate whether ROMA can replace expert ultrasound when IOTA is inconclusive. This prospective study involves one cancer centre and three general units. Women scheduled for an operation for a pelvic mass underwent a pelvic ultrasound pre-operatively. The final histology was obtained from the operative sample. The sensitivity, specificity and accuracy for each method were compared with the McNemar test. Of the 690 women included in the study, 171 (25%) had an inconclusive IOTA. In this group, expert ultrasound was more sensitive in diagnosing a malignant mass compared to ROMA (81% vs. 63%, p = 0.009) with no significant difference in the specificity or accuracy. All assessment methods involving IOTA had similar accuracies and were more accurate than RMI or ROMA alone. In conclusion, when IOTA was inconclusive, assessment by expert ultrasound was more sensitive than ROMA, with similar specificity.

1 January 2022 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
AHAya El Helali
Aya El Helali
SKShuk Tak Kwok
Shuk Tak Kwok
KTKa Yu Tse
Ka Yu Tse

31 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WCWan Kam Chiu
Wan Kam Chiu
SKShuk Tak Kwok
Shuk Tak Kwok
YWYaokai Wang
Yaokai Wang
HLHiu Mei Luk
Hiu Mei Luk
ACAaron Hei Yin Chan
Aaron Hei Yin Chan
KTKa Yu Tse
Ka Yu Tse
Lymph node status is important in predicting the prognosis and guiding adjuvant treatment in endometrial cancer. However, previous studies showed that systematic lymphadenectomy conferred no therapeutic values in clinically early-stage endometrial cancer but might lead to substantial morbidity and impact on the quality of life of the patients. The sentinel lymph node is the first lymph node that tumor cells drain to, and sentinel lymph node biopsy has emerged as an acceptable alternative to full lymphadenectomy in both low-risk and high-risk endometrial cancer. Evidence has demonstrated a high detection rate, sensitivity and negative predictive value of sentinel lymph node biopsy. It can also reduce surgical morbidity and improve the detection of lymph node metastases compared with systematic lymphadenectomy. This review summarizes the current techniques of sentinel lymph node mapping, the applications and oncological outcomes of sentinel lymph node biopsy in low-risk and high-risk endometrial cancer, and the management of isolated tumor cells in sentinel lymph nodes. We also illustrate a revised sentinel lymph node biopsy algorithm and advocate to repeat the tracer injection and explore the presacral and paraaortic areas if sentinel lymph nodes are not found in the hemipelvis.

26 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
HLHiu Mei Luk
Hiu Mei Luk
SNSiew Fei Ngu
Siew Fei Ngu
LLLesley Lau
Lesley Lau
KTKa Yu Tse
Ka Yu Tse
MCMandy Man-Yee Chu
Mandy Man-Yee Chu
KCKaren KL Chan
Karen KL Chan
This study aimed to assess the feasibility of patient-initiated follow-up (PIFU) in combination with regular tumour marker monitoring as an alternative to conventional hospital follow-up for ovarian cancer survivors. Women who had recently completed treatment for ovarian cancer and had a raised pre-treatment tumour marker were recruited. Participants were allocated to PIFU (intervention group) or conventional hospital follow-up (control group) according to their own preference. Both groups had regular tumour marker monitoring. The change in fear of cancer recurrence (FCR) score as measured by the FCR inventory, and the supportive care need (SCN) scores as measured by the SCN survey at baseline and at 6 months between PIFU and hospital follow-up were compared. Out of 64 participants, 37 (58%) opted for hospital follow-up and 27 (42%) opted for PIFU. During the 6-month study period, there was no significant difference in the change of FCR between the two groups (p = 0.35). There was a significant decrease in the sexuality unmet needs score in the intervention group from baseline to 6-month FU (mean difference −8.7, 95% confidence interval −16.1 to −1.4, p = 0.02). PIFU with tumour marker monitoring is a feasible follow-up approach in ovarian cancer survivorship care. FCR and SCN were comparable between PIFU and conventional hospital follow-up.

8 January 2025 in Anaesthesia
Verified
Journal Article
Open access
KTKa Yu Tse
Ka Yu Tse
MCMandy Man Yee Chu
Mandy Man Yee Chu
JCJessie Wan Kam Chiu
Jessie Wan Kam Chiu
SKShuk Tak Kwok
Shuk Tak Kwok
MIMichael Garnet Irwin
Michael Garnet Irwin
KCKaren KL Chan
Karen KL Chan
Summary: Introduction: Patients with advanced ovarian cancer often require radical cytoreductive surgery and chemotherapy, with or without targeted therapy. Return to intended oncological therapy after surgery is a crucial metric, as delay can worsen survival. The concept of return to intended oncological therapy is important because it highlights the need for not just successful surgical outcomes, but also the ability to continue with the comprehensive cancer treatment plan. Methods: A comprehensive review of the literature was conducted to identify relevant English language studies published from January 2010 to September 2024. Results: Delayed return to intended oncological therapy after surgery was associated with poor survival outcomes in ovarian cancer. This narrative review investigates how pre‐operative counselling and education; optimisation of the patient's medical condition; meticulous surgical planning and execution; early recognition of complications; and comprehensive postoperative care influence return to intended therapy in gynaecological surgery. Effective multidisciplinary care involving anaesthetists; nurses; physiotherapists; dietitians; psychologists; and the patient's relatives or friends, can prevent complications and ensure timely return to intended oncological therapy. Discussion: Awareness and management of factors affecting return to intended oncological therapy are essential for improving outcomes in patients with advanced ovarian cancer. We highlight the importance of multidisciplinary care (including enhanced recovery after surgery programmes) and the factors affecting these including age; nutrition; and occurrence of postoperative complications.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
JMJyoti Meena
Jyoti Meena
DBDipanwita Banerjee
Dipanwita Banerjee
SKSe Ik Kim
Se Ik Kim
HKhiroaki komatsu
hiroaki komatsu
SKShuk Tak Kwok
Shuk Tak Kwok
JNJoseph Noh
Joseph Noh
Meena J, et al. J Gynecol Oncol. 2025 Apr;36:e103. https://doi.org/10.3802/jgo.2025.36.e103